Research Library › Neuropeptides
Melanotan II (MT-II) is a synthetic cyclic lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a truncated seven-residue peptide designed to bind melanocortin receptors. It grew out of cyclic melanotropin designs published in 1989 by F. Al-Obeidi, Victor Hruby, Mac Hadley and colleagues at the University of Arizona. As of October 2026 it is not approved by the FDA or any other regulator, the FDA has acted against its sale as an unapproved drug, and an FDA advisory committee is scheduled to review it for compounding before the end of February 2027.
Key facts
| Type | Synthetic cyclic lactam heptapeptide; truncated analog of alpha-MSH |
|---|---|
| Other names | MT-II, MTII |
| Developed by | Victor Hruby, Mac Hadley, Robert Dorr and colleagues, University of Arizona |
| First described | 1989 (cyclic lactam alpha-melanotropin designs); first pilot human study published 1996 |
| Designed target | Melanocortin receptors (non-selective) |
| Regulatory status (Oct 2026) | Not FDA-approved; FDA enforcement against sale as an unapproved drug since 2007; removed from FDA Category 2 list April 2026; PCAC review scheduled before end of February 2027 |
Who developed it
Melanotan II was developed in the same University of Arizona laboratories that produced Melanotan I. Chemist Victor Hruby and biologist Mac Hadley led the design work, and pharmacologist Robert Dorr led its early clinical testing [1, 2, 3].
The university’s melanocortin patents were managed through Competitive Technologies, and the inventors later received royalties tied to Palatin Technologies, which developed the related compound PT-141 (bremelanotide) [3, 4].
Structure and design
Melanotan II is a shortened, ring-shaped (cyclic) version of alpha-MSH. In 1989 F. Al-Obeidi, Hruby, Hadley and B. M. Pettitt reported using molecular dynamics simulations to design a new class of cyclic alpha-MSH analogs. Replacing glycine with lysine allowed a lactam bridge to close the ring, and the resulting compound was reported to be far more potent and longer-acting than alpha-MSH in laboratory assays [1].
Hadley and Dorr later summarized Melanotan II as a cyclic, truncated peptide, in contrast to the linear Melanotan I [3]. Its sequence is commonly written Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Bremelanotide (PT-141) has the same ring but ends in a free acid instead of an amide, and a 2007 review described Melanotan II as the parent compound from which bremelanotide was derived [4].
Research history
- 1989: Design of superpotent cyclic lactam alpha-MSH analogs published in the Journal of the American Chemical Society [1]
- 1996: Dorr and colleagues publish a pilot Phase I study of Melanotan II in three volunteers in Life Sciences [2]
- Late 1990s to 2000s: Further clinical studies explore the compound in a research program on male erectile dysfunction; Palatin develops PT-141 as an analog [3]
- 2007: FDA warning letter to a company selling Melanotan II as an unapproved drug [5, 6]
- 2026: FDA removes Melanotan II from its Category 2 compounding list and schedules advisory committee review [7, 8]
Melanotan II was never taken through a full drug-approval program.
Regulatory status as of October 2026
Melanotan II is not approved by the FDA or any other regulator. In 2007 the FDA sent a warning letter to Melanocorp Inc. of Tennessee over the sale and marketing of Melanotan II as an unapproved new drug, and later letters stated that unapproved new drugs do not qualify for export. The case led to a criminal conviction and FDA debarment proceedings [5, 6].
On 15 April 2026 the FDA announced it would remove Melanotan II and 11 other peptides from its Category 2 list of bulk substances raising significant safety concerns for compounding [7]. Melanotan II was not on the agenda of the July 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. It is one of five peptides, with GHK-Cu, LL-37, dihexa acetate and PEG-MGF, scheduled for PCAC review before the end of February 2027 [7, 8]. Removal from Category 2 is not an approval, and as of October 2026 no PCAC vote on Melanotan II had taken place.
About this reference page
Kalibra Labs does not currently supply Melanotan II. This page is published as a neutral scientific and regulatory reference. Browse the Neuropeptides guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Who created Melanotan II?
Melanotan II was designed at the University of Arizona by a team including Victor Hruby, Mac Hadley and F. Al-Obeidi, with Robert Dorr leading early clinical work [1, 2].
Is Melanotan II FDA approved?
No. As of October 2026 Melanotan II is not FDA-approved, and the FDA has treated its sale as an unapproved new drug since at least 2007 [5, 6].
When will the FDA advisory committee review Melanotan II?
The FDA has scheduled Melanotan II for Pharmacy Compounding Advisory Committee review before the end of February 2027; no date had been announced as of October 2026 [7, 8].
How is Melanotan II related to PT-141?
PT-141 (bremelanotide) was derived from Melanotan II. The two share the same cyclic structure, but bremelanotide ends in a free acid rather than an amide [4].
Sources
- Al-Obeidi F, Hruby VJ, Hadley ME, Pettitt BM. Design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamic simulations. J Am Chem Soc. 1989;111(9):3413-3416. doi:10.1021/ja00191a044. Link
- Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. doi:10.1016/0024-3205(96)00160-9. Link
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029. Link
- Bridges TM. Molecule of the month: bremelanotide. Curr Top Med Chem. 2007;7(11):1152. doi:10.2174/156802607780906582. Link
- U.S. FDA, Office of Enforcement and Import Operations. Notice of opportunity for hearing on proposal to debar (Melanocorp, Melanotan II), Docket No. FDA-2015-N-4169. Link
- Drug Topics. FDA issues warning letter to Melanocorp. 7 Sep 2007. Link
- Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 "do not compound" list. 16 Apr 2026. Link
- DLA Piper. FDA AdComm recommends adding six peptides to bulk list. 31 Jul 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
